CLYM

Climb Bio Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↓ 1/10
  • Value↑ 5/10
Climb Bio sales and earnings growth
CLYM Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 65.16%
  • FCF Y/Y↓ -83.32%
Climb Bio gross and profit margin trends
CLYM Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -106.63%
Climb Bio net debt vs free cash flow
CLYM Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Climb Bio stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks